BioNTech-Pfizer Say Covid Vaccine 100% Effective On 12-15 Year Olds

Phase 3 trials carried out on 2,260 adolescents in the United States "demonstrated 100 percent efficacy and robust antibody responses", the companies said in a statement.

BioNTech-Pfizer said Wednesday their vaccine showed 100 percent efficacy against the coronavirus in 12 to 15 year olds, as they eye approval for adolescents to get the jabs before the next school year. Phase 3 trials carried out on 2,260 adolescents in the United States "demonstrated 100 percent efficacy and robust antibody responses", the companies said in a statement. "We plan to submit these data to (US regulator) FDA as a proposed amendment to our Emergency Use Authorisation in the coming weeks and to other regulators around the world, with the hope of starting to vaccinate this age group before the start of the next school year," said Pfizer chief executive Albert Bourla. Chief executive of German company BioNTech said the results showing high protection for teens were "very encouraging given the trends we have seen in recent weeks regarding the spread of the B.1.1.7 UK variant".